Human Growth Hormone (HGH / Somatropin): FDA-Approved Uses, How It Works, Side Effects and the Truth About Off-Label Use
- Dr. Ryan Heals, Pharm.D.
- 15 hours ago
- 10 min read
Human growth hormone — known medically as somatropin in its synthetic recombinant form, and widely referred to as HGH — is one of the most scientifically important, frequently misrepresented, and legally complex medicines in modern pharmacology. On one hand, it is a life-transforming treatment for children with growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome, and for adults with documented growth hormone deficiency from pituitary disease. On the other hand, it is the subject of a vast and largely unregulated off-label market for anti-aging, body composition, and athletic performance — a market that runs far ahead of the available evidence and that carries genuine legal, safety, and financial risks for consumers.
Understanding the distinction between these two worlds — what HGH demonstrably does, what it is legally approved to treat, and where the evidence for non-medical use actually stands — is what this guide is about.
Somatropin is a 191-amino-acid recombinant protein biologically identical to endogenous human growth hormone secreted by the anterior pituitary gland. It has been available since 1985 — when the FDA approved the first recombinant version, replacing the prior practice of extracting growth hormone from cadaveric human pituitary glands (which was discontinued due to the risk of Creutzfeldt-Jakob disease). Today multiple brands — Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others — are FDA-approved for use in specific clinical conditions in the United States.
Drugs.com provides comprehensive somatropin information, last updated April 21, 2026 at: https://www.drugs.com/somatropin.html
How HGH Works — The Growth Hormone Axis
Growth hormone (GH) is a peptide hormone produced by somatotroph cells in the anterior pituitary gland. Its release is regulated by two hypothalamic hormones — growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it. Secretion is pulsatile — with the largest pulse occurring during deep slow-wave sleep, which is why sleep quality directly affects GH levels.
The primary mechanism — IGF-1 axis:
Growth hormone acts on multiple tissues through two complementary mechanisms. Directly, it acts on adipose tissue to stimulate lipolysis (fat breakdown), acts on the liver and other tissues to influence metabolism, and acts on cells to modulate gene expression. Indirectly — and most importantly for growth — it stimulates the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 then acts on:
Bone growth plates (epiphyseal plates) — stimulating longitudinal bone growth; this is why HGH causes height increase only in children with open growth plates
Muscle tissue — promoting protein synthesis and muscle cell proliferation
Most other tissues — influencing metabolism, cellular repair, and regeneration
Why HGH does not make adults taller:
Once the growth plates in bones have fused — which typically occurs in the late teenage years — HGH cannot stimulate further longitudinal bone growth. This is one of the most important facts for patients to understand: HGH given to healthy adults with closed epiphyses cannot increase height. Any product marketed as "HGH for height" in adults is making a physiologically impossible claim.
Natural growth hormone secretion across the lifespan:
GH secretion peaks during puberty and declines progressively with age — falling approximately 14% per decade after age 30. This age-related decline is entirely normal and is not the same as growth hormone deficiency. Treating normal age-related GH decline as if it were a deficiency disease is one of the central misconceptions driving the anti-aging HGH market.
FDA-Approved Indications for Somatropin — The Complete List
As of 2026, somatropin is FDA-approved for the following specific indications. Approval is for the medicine in these conditions — not for general anti-aging, performance, or cosmetic use:
In children:
Growth hormone deficiency (GHD) — the primary and most well-established indication; children produce insufficient GH from the pituitary due to congenital or acquired causes
Turner syndrome — a chromosomal condition (45,X) affecting females, causing short stature and other developmental features; GH treatment significantly improves adult height
Prader-Willi syndrome (PWS) — a genetic disorder causing hypotonia, hyperphagia, obesity, and growth failure; GH improves body composition, muscle tone, and growth; only when confirmed by genetic testing
Idiopathic short stature (ISS) — short stature of unknown cause in children with open growth plates who are significantly below normal height for their age and predicted adult height
Small for gestational age (SGA) — children born significantly smaller than normal who fail to achieve catch-up growth by ages 2–4 years
SHOX deficiency — haploinsufficiency of the short-stature homeobox gene causing short stature
Noonan syndrome — a genetic condition with short stature; GH approved for height improvement
Chronic renal insufficiency — in paediatric patients before kidney transplantation; GH improves growth
In adults:
Adult growth hormone deficiency (AGHD) — either of childhood onset (continuing into adulthood) or adult onset (from pituitary disease, surgery, radiation, or trauma); requires confirmation by GH stimulation testing showing inadequate GH secretion
HIV-associated wasting / cachexia — Serostim brand specifically; approved for muscle wasting in AIDS
Short bowel syndrome — Zorbtive brand specifically; used alongside nutritional support
Important: This is the complete FDA-approved indication list. Nothing else is approved.
Adult Growth Hormone Deficiency — What Genuine Deficiency Looks Like
Adult GHD is a real and important medical condition — distinct from the normal decline in GH with ageing. It typically results from:
Pituitary tumours (craniopharyngioma, pituitary adenoma) or their treatment (surgery, radiotherapy)
Traumatic brain injury
Subarachnoid haemorrhage
Other hypothalamic or pituitary disease
Symptoms of genuine adult GHD:
Increased body fat — particularly central (abdominal) fat
Reduced muscle mass and strength
Decreased bone density — increased fracture risk
Fatigue and reduced exercise capacity
Impaired quality of life — often including depression, anxiety, and poor wellbeing
Increased cardiovascular risk — unfavourable lipid profile, increased carotid intima-media thickness
Altered body composition — the characteristic "middle-age spread" of GHD patients
Diagnosis requires provocative GH stimulation testing — a single random GH level is meaningless because of GH's pulsatile secretion. The insulin tolerance test (ITT) or GHRH-arginine stimulation test are the gold-standard diagnostic tools. IGF-1 levels provide supporting evidence.
Benefits of GH replacement in confirmed adult GHD:
Normalises body composition — reduces fat mass, increases lean muscle mass
Improves bone mineral density
Improves lipid profile (reduces LDL, increases HDL)
Significantly improves quality of life and psychological wellbeing
Reduces cardiovascular risk markers
These benefits are well-documented in randomised controlled trials and long-term registry data. They are real — but they apply specifically to patients with documented growth hormone deficiency, not to healthy adults with normal-but-declining GH.
HGH Side Effects — What Patients and Prescribers Must Know
Somatropin at therapeutic doses in indicated patients is generally well tolerated. Side effects are mostly related to fluid retention and the metabolic effects of elevated IGF-1:
Common side effects:
Peripheral oedema — fluid retention causing swelling of hands, feet, and ankles; common at initiation, usually resolves
Joint pain (arthralgia) and muscle pain (myalgia) — fluid shifts in joint spaces; often dose-dependent
Carpal tunnel syndrome — fluid retention compresses the median nerve at the wrist; numbness and tingling in the hand; usually resolves with dose reduction
Headache
Injection site reactions — redness, bruising, pain, or lipoatrophy (fat loss at injection sites)
Less common / requiring monitoring:
Increased blood glucose / insulin resistance — GH is physiologically anti-insulin; can precipitate or worsen diabetes; monitor fasting glucose and HbA1c regularly
Intracranial hypertension (benign) — rare; headaches, visual disturbances; resolves with dose reduction
Fluid retention and weight gain — particularly at initiation
Special populations requiring extra caution:
Prader-Willi syndrome — particularly important to exclude upper airway obstruction and severe obesity before starting GH; case reports of respiratory failure in PWS patients on GH with unrecognised sleep apnea; respiratory assessment before initiation is mandatory
Active malignancy — GH is absolutely contraindicated in patients with active cancer; GH stimulates cell proliferation through IGF-1 and could theoretically accelerate tumour growth
Long-term safety monitoring (SAGhE cohort):
The SAGhE (Safety and Appropriateness of Growth Hormone treatments in Europe) multinational cohort has followed children treated with GH into adulthood for decades. No consistent excess cancer mortality has been demonstrated in most analyses, though some individual country analyses have raised signals for specific cancer types that are actively monitored. This data provides reasonable reassurance for therapeutic use in indicated patients while emphasising the importance of using the minimum effective dose.
The Off-Label HGH Market — What the Evidence Actually Shows
The anti-aging, body composition, and athletic performance HGH market is large, growing, and largely unsupported by the evidence needed to justify the legal and medical risks involved:
What the research shows in healthy adults:
Systematic reviews of GH administration in healthy adults without deficiency (including a 2007 Annals of Internal Medicine meta-analysis of 31 RCTs) consistently show:
Modest reductions in fat mass — typically 2–4 kg
Modest increases in lean mass — typically 2–3 kg, representing fluid rather than contractile muscle protein in most studies
No consistent improvement in muscle strength or physical performance
No demonstrated improvement in athletic performance or endurance
No consistent benefit on quality of life or cognitive function in healthy adults
What healthy adults actually experience:
The side effects are the same as in patients with deficiency — fluid retention, joint pain, carpal tunnel syndrome, glucose intolerance — but occur in people who had no clinical need for the treatment. The risk-benefit ratio in healthy adults is fundamentally different from patients with documented deficiency.
The legal reality — this is critical:
Under the Anti-Drug Abuse Act of 1990 (21 USC 333(e)), distribution or possession of HGH for any purpose other than the treatment of a disease or other recognised medical condition is a federal felony in the United States — punishable by up to 5 years imprisonment. This applies to anti-aging clinics, wellness centres, and individuals alike. The DEA and state medical boards have pursued criminal and administrative actions against prescribers operating in the non-medical HGH market. This is not a grey area — it is federal law.
Internet-purchased "HGH" products:
Products sold online as "HGH supplements," "HGH releasers," or "homeopathic HGH" are not somatropin. Real somatropin is a large protein molecule (191 amino acids) that cannot survive oral ingestion — it is destroyed by gastric acid before absorption. Any oral, sublingual, or topical product claiming to deliver human growth hormone is making a scientifically impossible claim. If it actually contained somatropin, it would be illegal to sell without a prescription.
Approved HGH Brands in the USA — 2026 Overview
Brand | Manufacturer | Formulation | Notable Feature |
Norditropin (somatropin) | Novo Nordisk | Pre-filled pen | Most widely prescribed; liquid formulation; pen device |
Genotropin | Pfizer | Two-chamber cartridge | Powder + diluent mixed at use; multiple strengths |
Humatrope | Eli Lilly | Cartridge + vial | Long-established brand |
Saizen | EMD Serono | Powder for reconstitution | Click.easy auto-injector option |
Omnitrope | Sandoz | Biosimilar somatropin | First FDA-approved biosimilar GH; lower cost |
Serostim | EMD Serono | Powder for reconstitution | Specific FDA approval for HIV wasting only |
Zorbtive | EMD Serono | Powder for reconstitution | Specific FDA approval for short bowel syndrome only |
Sogroya (somapacitan) | Novo Nordisk | Once-weekly pen | Long-acting; once-weekly dosing in adults with GHD |
2026 Update — Long-Acting Growth Hormone
A significant development in 2026 is the growing availability of long-acting growth hormone (LAGH) formulations designed to replace daily injections with weekly dosing:
Sogroya (somapacitan) — FDA-approved for adult GHD:
Once-weekly subcutaneous injection; a reversible albumin-binding GH derivative. Approved by FDA in August 2020 for adult GHD and represents a meaningful quality-of-life improvement over daily injections for adults requiring GH replacement.
Ngenla (somatrogon) — approved in multiple countries for paediatric GHD; the FDA issued a Complete Response Letter in 2022 and approval in the USA is pending as of 2026.
These LAGH products are being studied for improved adherence, as daily injection burden is a significant driver of non-adherence in both paediatric and adult GHD patients.
For our complete guide on testosterone deficiency — which frequently coexists with adult GHD and requires similar specialist evaluation: [Testosterone Deficiency (Low T): Symptoms, Causes and Treatment]
For our guide on erectile dysfunction — which is more common in men with pituitary disease affecting both GH and testosterone: [Erectile Dysfunction: Causes, Symptoms and Complete Treatment Guide]
For our guide on enclomiphene and testosterone support — a related hormonal health topic increasingly researched alongside GHD: [Enclomiphene for Men: Testosterone Support, Fertility and Clinical Evidence]
WebMD provides a comprehensive HGH overview, medically reviewed June 7, 2026 at: https://www.webmd.com/fitness-exercise/human-growth-hormone-hgh
The FDA's official Norditropin prescribing information, updated 2025 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf
Frequently Asked Questions
Is HGH legal in the USA without a prescription?
No. Somatropin (recombinant human growth hormone) is a prescription-only controlled substance. Under the Anti-Drug Abuse Act of 1990 (21 USC 333(e)), distributing or possessing HGH for any purpose other than the treatment of a specific disease or recognised medical condition is a federal felony in the United States, carrying penalties of up to 5 years imprisonment. This includes anti-aging, bodybuilding, and athletic performance use. A valid prescription from a licensed physician for an FDA-approved indication is required for any legal HGH use in the USA.
What are the signs of growth hormone deficiency in adults?
Adult GHD produces a characteristic clinical picture: increased central (abdominal) fat despite normal or unchanged eating, loss of muscle mass and strength, fatigue and reduced exercise capacity, reduced bone density, psychological symptoms including depression and poor wellbeing, and an unfavourable cardiovascular risk profile (elevated LDL, reduced HDL). Many of these features overlap with normal ageing, which is why diagnosis requires formal provocative GH stimulation testing — not simply a low random GH or IGF-1 level, as these are insufficient to diagnose deficiency.
Does HGH actually work for anti-aging?
In healthy adults without GH deficiency, the evidence for anti-aging benefits of HGH is not compelling. Meta-analyses of randomised controlled trials in healthy adults consistently show modest reductions in fat mass and increases in lean mass but no improvement in muscle strength, physical performance, quality of life, or longevity. The fluid retention that accounts for much of the lean mass increase reverses when treatment stops. Meanwhile, side effects — joint pain, carpal tunnel syndrome, glucose intolerance — are real. In patients with documented GHD, the benefits are clearly demonstrated — but these patients are being treated for a medical deficiency, not for the normal ageing process.
Can HGH treat obesity or help with weight loss?
HGH is not FDA-approved for obesity treatment or weight loss. In patients with adult GHD, GH replacement does reduce fat mass — particularly abdominal fat — as part of correcting the deficiency-related body composition changes. However, in healthy non-deficient overweight or obese adults, GH use for weight loss is not supported by robust evidence, carries significant side effects, is extremely expensive, and is illegal without a medical diagnosis. Established obesity treatments — lifestyle modification, anti-obesity medications approved by the FDA — are the appropriate clinical pathway.
What is the difference between somatropin and "HGH supplements" sold online?
Somatropin is a 191-amino-acid protein that must be administered by injection — it cannot survive oral ingestion because gastric acid and digestive enzymes destroy it before any absorption occurs. Any product sold as an oral, sublingual, or topical "HGH supplement" or "HGH releaser" cannot contain real somatropin — if it did, it would be biologically inactive when taken orally, and its sale without a prescription would be a federal felony. Such products typically contain amino acids, herbal extracts, or vitamins that may modestly stimulate natural GH release — but are not somatropin, produce far smaller effects, and do not replicate therapeutic HGH replacement in any meaningful way.
Comments